Cancer Research and Treatment

Original Articles

General

Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel: Sangmoon Lee, Jin Roh, Jun Sung Park, Islam Oguz Tuncay, Wonchul Lee, Jung-Ah Kim, Brian Baek-Lok Oh, Jong-Yeon Shin, Jeong Seok Lee, Young Seok Ju, Ryul Kim, Seongyeol Park, Jaemo Koo, Hansol Park, Joonoh Lim, Erin Connolly-Strong, Tae-Hwan Kim, Yong Won Choi, Mi Sun Ahn, Hyun Woo Lee, Seokhwi Kim, Jang-Hee Kim, Minsuk Kwon; Cancer Res Treat. 2025;57(2):350-361. Published online September 19, 2024; DOI: https://doi.org/10.4143/crt.2024.114

Abstract PDF Supplementary Material PubReader ePub: Purpose
Cancer poses a significant global health challenge, demanding precise genomic testing for individualized treatment strategies. Targeted-panel sequencing (TPS) has improved personalized oncology but often lacks comprehensive coverage of crucial cancer alterations. Whole-genome sequencing (WGS) addresses this gap, offering extensive genomic testing. This study demonstrates the medical potential of WGS.
Materials and Methods
This study evaluates target-enhanced WGS (TE-WGS), a clinical-grade WGS method sequencing both cancer and matched normal tissues. Forty-nine patients with various solid cancer types underwent both TE-WGS and TruSight Oncology 500 (TSO500), one of the mainstream TPS approaches.
Results
TE-WGS detected all variants reported by TSO500 (100%, 498/498). A high correlation in variant allele fractions was observed between TE-WGS and TSO500 (r=0.978). Notably, 223 variants (44.8%) within the common set were discerned exclusively by TE-WGS in peripheral blood, suggesting their germline origin. Conversely, the remaining subset of 275 variants (55.2%) were not detected in peripheral blood using the TE-WGS, signifying them as bona fide somatic variants. Further, TE-WGS provided accurate copy number profiles, fusion genes, microsatellite instability, and homologous recombination deficiency scores, which were essential for clinical decision-making.
Conclusion
TE-WGS is a comprehensive approach in personalized oncology, matching TSO500’s key biomarker detection capabilities. It uniquely identifies germline variants and genomic instability markers, offering additional clinical actions. Its adaptability and cost-effectiveness underscore its clinical utility, making TE-WGS a valuable tool in personalized cancer treatment.

2,057 View
215 Download

VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma: Seongyeol Park, Soo Jeong Nam, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, J. Hun Hah, Tack-Kyun Kwon, Dong-Wan Kim, Myung-Whun Sung, Dae Seog Heo, Yung-Jue Bang; Cancer Res Treat. 2016;48(2):518-526. Published online July 14, 2015; DOI: https://doi.org/10.4143/crt.2015.093

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to evaluate potential prognostic factors in patients with adenoid cystic carcinoma (ACC). Materials and Methods A total of 68 patients who underwent curative surgery and had available tissue were enrolled in this study. Their medical records and pathologic slides were reviewed and immunohistochemistry for basic fibroblast growth factor, fibroblast growth factor receptor (FGFR) 2, FGFR3, c-kit, Myb proto-oncogene protein, platelet-derived growth factor receptor beta, vascular endothelial growth factor (VEGF), and Ki-67 was performed. Univariate and multivariate analysis was performed for determination of disease-free survival (DFS) and overall survival (OS).
Results
In univariate analyses, primary site of nasal cavity and paranasal sinus (p=0.022) and Ki-67 expression of more than 7% (p=0.001) were statistically significant factors for poor DFS. Regarding OS, perineural invasion (p=0.032), high expression of VEGF (p=0.033), and high expression of Ki-67 (p=0.007) were poor prognostic factors. In multivariate analyses, primary site of nasal cavity and paranasal sinus (p=0.028) and high expression of Ki-67 (p=0.004) were independent risk factors for poor DFS, and high expression of VEGF (p=0.011) and Ki-67 (p=0.011) showed independent association with poor OS. Conclusion High expression of VEGF and Ki-67 were independent poor prognostic factors for OS in ACC.

Citations

Citations to this article as recorded by

PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands
Vasudha Mishra, Alka Singh, Michael Korzinkin, Xiangying Cheng, Claudia Wing, Viktoria Sarkisova, Ashwin L. Koppayi, Alexandra Pogorelskaya, Oksana Glushchenko, Manu Sundaresan, Venkat Thodima, Jack Carter, Koichi Ito, Peggy Scherle, Anna Trzcinska, Ivan
Journal of Experimental & Clinical Cancer Research.2025;[Epub] CrossRef
Vascular Endothelial Growth Factor Receptor Inhibitors for Recurrent or Metastatic Adenoid Cystic Carcinoma
Camilla O. Hoff, Joao Manzi, Felippe Lazar Neto, Renata Ferrarotto
JAMA Otolaryngology–Head & Neck Surgery.2024; 150(7): 587. CrossRef
Sinonasal adenoid cystic carcinoma: preoperative apparent diffusion coefficient histogram analysis in prediction of prognosis and Ki-67 proliferation status
Jingfeng Cheng, Quan Liu, Yuzhe Wang, Yang Zhan, Yin Wang, Dandan Shen, Yue Geng, Linying Guo, Zuohua Tang
Japanese Journal of Radiology.2024;[Epub] CrossRef
Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials
Youjin Kim, Bhumsuk Keam, Eun Joo Kang, Jin-Soo Kim, Hye Ryun Kim, Keun-Wook Lee, Jung Hye Kwon, Kyoung Eun Lee, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Moon Young Choi, Ki Hyeong Lee, Sung-Bae Kim, Myung-Ju Ahn
Cancer Research and Treatment.2024; 56(4): 1068. CrossRef
Interactive role of miR‐29, miR‐93, miR‐205, and VEGF in salivary adenoid cystic carcinoma
Parisa Bayat, Nazanin Mahdavi, Shima Younespour, Neda Kardouni Khoozestani
Clinical and Experimental Dental Research.2023; 9(1): 112. CrossRef
Current understanding of adenoid cystic carcinoma in the gene expression and targeted therapy
Quan-Quan Lin, Jin-Long Sun, Feng Wang, Hai-Zhong Zhang, Ge Zhou, Qing Xi
Holistic Integrative Oncology.2023;[Epub] CrossRef
Molecular Biology and Therapeutic Targets of Primitive Tracheal Tumors: Focus on Tumors Derived by Salivary Glands and Squamous Cell Carcinoma
Alessandro Marchioni, Roberto Tonelli, Anna Valeria Samarelli, Gaia Francesca Cappiello, Alessandro Andreani, Luca Tabbì, Francesco Livrieri, Annamaria Bosi, Ottavia Nori, Francesco Mattioli, Giulia Bruzzi, Daniele Marchioni, Enrico Clini
International Journal of Molecular Sciences.2023; 24(14): 11370. CrossRef
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Glenn J. Hanna, Myung-Ju Ahn, Jameel Muzaffar, Bhumsuk Keam, Daniel W. Bowles, Deborah J. Wong, Alan L. Ho, Sung-Bae Kim, Francis Worden, Tak Yun, Xianzhang Meng, Jan M. Van Tornout, Maureen G. Conlan, Hyunseok Kang
Clinical Cancer Research.2023; 29(22): 4555. CrossRef
A Contemporary Review of Molecular Therapeutic Targets for Adenoid Cystic Carcinoma
Lauren E. Miller, Vivienne Au, Tara E. Mokhtari, Deborah Goss, Daniel L. Faden, Mark A. Varvares
Cancers.2022; 14(4): 992. CrossRef
Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma
Luana Guimaraes de Sousa, Felippe Lazar Neto, Jessica Lin, Renata Ferrarotto
Current Oncology Reports.2022; 24(5): 621. CrossRef
Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments
Luana Guimaraes de Sousa, Katarina Jovanovic, Renata Ferrarotto
Current Treatment Options in Oncology.2022; 23(8): 1135. CrossRef
The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?
Robbert Cleymaet, Tijl Vermassen, Renaat Coopman, Hubert Vermeersch, Stijn De Keukeleire, Sylvie Rottey
International Journal of Molecular Sciences.2022; 23(23): 14891. CrossRef
Approaches to the Management of Metastatic Adenoid Cystic Carcinoma
Rex H. Lee, Katherine C. Wai, Jason W. Chan, Patrick K. Ha, Hyunseok Kang
Cancers.2022; 14(22): 5698. CrossRef
Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy
James Nightingale, Benedict Lum, Rahul Ladwa, Fiona Simpson, Benedict Panizza
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2021; 1875(2): 188523. CrossRef
Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study
Guopei Zhu, Lin Zhang, Shengjin Dou, Rongrong Li, Jiang Li, Lulu Ye, Wen Jiang, Minjun Dong, Min Ruan, Wenjun Yang, Chenping Zhang
Therapeutic Advances in Medical Oncology.2021;[Epub] CrossRef
Impact of tumor site on the prognosis of salivary gland neoplasms: A systematic review and meta-analysis
Erison Santana dos Santos, Carla Isabelly Rodrigues-Fernandes, Paul M. Speight, Syed Ali Khurram, Ibrahim Alsanie, Ana Gabriela Costa Normando, Ana Carolina Prado-Ribeiro, Thaís Bianca Brandão, Luiz Paulo Kowalski, Eliete Neves Silva Guerra, Marcio Ajudar
Critical Reviews in Oncology/Hematology.2021; 162: 103352. CrossRef
Molecular Markers that Matter in Salivary Malignancy
Katherine C. Wai, Hyunseok Kang, Patrick K. Ha
Otolaryngologic Clinics of North America.2021; 54(3): 613. CrossRef
Asymptomatic Palatal Mass
C. V. Divyambika, K. Satish Srinivas, S. Sathasiva Subramanian, S. Elengkumaran, N. Malathi
Indian Journal of Dental Research.2021; 32(1): 120. CrossRef
Anlotinib is effective in patients with advanced oral cancer?
Chen Chu, Wei Shang, Yan Sun, Xiaochun Zhang
Medical Hypotheses.2020; 137: 109578. CrossRef
Shallow whole genome sequencing of adenoid cystic carcinomas of the salivary glands identifies specific chromosomal aberrations related to tumor progression
R. Cordesmeyer, R. Laskawi, H. Schliephake, P. Kauffmann, J. Beck, K. Bornemann-Kolatzki, E. Schütz, P. Ströbel, S. Kueffer, A. Fichtner, F. Bremmer
Oral Oncology.2020; 103: 104615. CrossRef
Knockdown Rab11‐FIP2 inhibits migration and invasion of nasopharyngeal carcinoma via suppressing Rho GTPase signaling
Guofei Feng, Liting Qin, Zhipeng Liao, Xiling Xiao, Bo Li, Wanmeng Cui, Libin Liang, Yingxi Mo, Guangwu Huang, Ping Li, Xiaoying Zhou, Zhe Zhang, Xue Xiao
Journal of Cellular Biochemistry.2020; 121(2): 1072. CrossRef
Major and minor salivary gland tumours
Gemma Gatta, Marco Guzzo, Laura D. Locati, Mark McGurk, Franz Josef Prott
Critical Reviews in Oncology/Hematology.2020; 152: 102959. CrossRef
The value of MYB as a prognostic marker for adenoid cystic carcinoma: Meta‐analysis
Xiangqi Liu, Dongru Chen, Xiaomei Lao, Yujie Liang
Head & Neck.2019; 41(5): 1517. CrossRef
New approaches in salivary gland carcinoma
Caroline Even, Neus Baste, Marion Classe
Current Opinion in Oncology.2019; 31(3): 169. CrossRef
Study of MYB-NFIB chimeric gene expression, tumor angiogenesis, and proliferation in adenoid cystic carcinoma of salivary gland
Junya Ono, Yasuo Okada
Odontology.2018; 106(3): 238. CrossRef
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma
A.L. Ho, L. Dunn, E.J. Sherman, M.G. Fury, S.S. Baxi, R. Chandramohan, S. Dogan, L.G.T. Morris, G.D. Cullen, S. Haque, C.S. Sima, A. Ni, C.R. Antonescu, N. Katabi, D.G. Pfister
Annals of Oncology.2016; 27(10): 1902. CrossRef
The role of perineural invasion on head and neck adenoid cystic carcinoma prognosis: a systematic review and meta-analysis
Jun Ju, Yun Li, Juan Chai, Chao Ma, Qianwei Ni, Zhiyuan Shen, Jianhua Wei, Moyi Sun
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2016; 122(6): 691. CrossRef

14,335 View
127 Download
32 Web of Science
27 Crossref

First
Prev
Page of 1
Next
Last

Search